Patient related outcomes in a real life prospective follow up study: Allergen immunotherapy increase quality of life and reduce sick days

Table 3 Three models of predicting loss of the diagnoses of rhino-conjunctivitis (RC) (=1) at follow-up

	*Model one With RQLQ* in the model**			*Model two With 15D-score in the model*			*Model three With EQ-5D-score in the model*
	Coefficient	Std. Err	P-value	Coefficient	Std. Err	P-value	Coefficient	Std. Err	P-value
Gender – male	−0.900	0.754	0.232	−0.733	0.725	0.312	−0.696	0.722	0.335
Age at inclusion	0.069	0.029	0.018*	0.067	0.029	0.020*	0.070	0.029	0.018*
Body mass index	−0.126	0.093	0.175	−0.123	0.100	0.218	−0.122	0.102	0.233
Vaccination modality House dust mites only	1.432	0.992	0.149	1.421	0.988	0.150	1.464	0.981	0.136
Grass pollen and house dust mites	1.367	0.808	0.091	1.697	0.762	0.026*	1.638	0.766	0.032*
HRQoL^^-scores at baseline	−0.683	0.500	0.172	2.989	4.469	0.504	1.905	2.186	0.383
Vaccination place – private clinic	1.033	1.193	0.387	0.890	1.144	0.437	0.940	1.147	0.412
Constant	−1.842	2.750	0.503	−6.343	3.941	0.108	−5.352	2.675	0.045
Number of observations	245			244			241
LR chi²	17.76			16.21			16.96
Prob > chi²	0.0131			0.0232			0.0177
Pseudo R²	0.1979			0.1808			0.1897

ISSN: 1939-4551